-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the information in the Yaodu database, the status of the PD-L1/FGFR dual-mechanism small molecule regulator/inhibitor FH-2001 capsule declared by Shanghai Fosun Pharmaceutical Industry Development Co.
According to the information in the Yaodu database, the status of the PD-L1/FGFR dual-mechanism small molecule regulator/inhibitor FH-2001 capsule declared by Shanghai Fosun Pharmaceutical Industry Development Co.
Wang Qian summarized PD-1/PD-L1 in the article "Summary of Patent Research Progress of PD-1/PD-L1 Small Molecule Inhibitors" (Source: Shanghai Medicine, 2019,40(17):76-80) After the advantages of small molecule inhibitors compared with PD-1/PD-L1 antibodies, the latest research progress in patent reports in this field is briefly reviewed
Based on Wang Qian's article, the author conducted a more detailed analysis of the core patent applications and technology distribution of PD-1/PD-L1 small molecule inhibitors in China
1.
Search formula: Keyword=PD AND (Categorization number=(C07 AND A61) NOT C07K)
2.
2.
2.
2.
Figure 1.
Figure 2 Distribution of current legal status of all applications
It can be seen from Figure 1 that the earliest Chinese compound patent application for PD-1/PD-L1 small molecule inhibitors detected in this article was in 2014, and the number of applications from 2014 to 2019 showed an overall upward trend year by year
2.
2.
It can be seen from Table 1 that the current Chinese compound patent applicants for PD-1/PD-L1 small molecule inhibitors are mostly domestic applicants, including a large number of applicants from universities and scientific research institutes, and some domestic applicants The layout of the overseas family has also been carried out
2.
2.
2.
4 Liveness data
4 Liveness data
Table 3 Activity data in each patent (application) (only those who applied for and disclosed the activity data since 2019)
3.
Summary
Summary
With the improvement of China's patent system and the annual growth of the pharmaceutical market, foreign pharmaceutical companies are paying more and more attention to China's patent layout.
Therefore, the analysis of Chinese patents (applications) can probably reflect the development status of a certain technical field.
And prospects
.
This article analyzes the selected PD-1/PD-L1 small molecule inhibitor Chinese compound patents and found that:
The research and development of PD-1/PD-L1 small molecule inhibitors started relatively late, and their technology is still in the development stage;
The Chinese compound patent applicants for PD-1/PD-L1 small molecule inhibitors are mainly domestic applicants, including many universities and research institutes
.
In the past two years, the PD-1/PD-L1 small molecule inhibitors that have applied for compound patents in China have the lowest IC50 for PD-1/PD-L1.
Most of them are less than 100nM, and even less than 10nM or even 1nM
.
However, because the development of PD-1/PD-L1 small molecule inhibitors started relatively late, there are currently no clinical trials, so whether these compounds can compete with macromolecular antibodies in terms of safety/effectiveness? Even instead, there are still many uncertain factors
.
